WHAT THE MEDIA SAY: Cipro supply taxes the US Government

Organisation: Bayer

Issue: Supply of antibiotic Cipro to US Government



It was hailed as the 'wonder drug of the anthrax scare' (The Times,

19/10) that had 'revitalised its moribund German manufacturer, Bayer'

(The Independent, 23/10).



But the supply of the powerful antibiotic, Cipro, to the US Government

in the wake of the recent anthrax attacks in America soon saw the

headlines turning sour as Bayer and government officials found

themselves deep in controversy amid claims that the German drugs

conglomerate could not meet demand.



Calls to override Cipro's patent and order cheap copies put the US

Government in an 'embarrassing predicament' (bbc.co.uk, 29/10).



'On drug patents the US never budges,' advised The Guardian (23/10), but

just 24 hours later it was reporting the U-turn of US health secretary

Tommy Thompson.



It was later said that he had used 'strong-arm negotiating tactics'

(nytimes.com, 29/10) and put 'pragmatism before ideology'

(startribune.com, 29/10) in threatening to suspend the patent if the

cost of Cipro was not reduced.



Bayer 'bowed to demands' (The Guardian, 25/10) and slashed the

price.



Meanwhile, the Canadian Government - earlier widely reported as having

'thrown the Cipro patent out of the window' (The Times, 22/10) -

capitulated in the face of legal threats from Bayer and the drug

industry was once again lambasted.



'Cipro saga exposes how drug-makers protect profits,' ran the headline

on usatoday.com (29/10).



On the same day, ananova.com was reporting that Cipro had been 'dropped

as the first choice of drug by US health officials'. This was later

denied by Bayer spokesperson, Michael Diehl.



Nobody can claim to have come out of the debacle with their reputation

intact.



And whatever happens next on the patent issue, many believe that the

damage to the reputations of those involved has already been done.



As The Sunday Telegraph's (28/10) Richard Fletcher pointed out: 'The

rights and wrongs of drug patents and responsibilities are no longer

just an issue for the liberal classes.'



Businessweek.com (29/10) agreed: 'The very stability of the drug patent

system may be in question.'



Analysis and commentary by Echo Research. More information can be found

at: www.echoResearch.com.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.